Despite these risks, the NASPGHAN guidelines recommend liver biopsy in patients with increased levels of ALT (>80 U/L), AAR >1, or splenomegaly, altogether defining a high risk of MASH and/or advanced fibrosis [80]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.